Boehringer Ingelheim International GmbH to partner with Carthronix, a biopharmaceutical company to develop therapies based on small molecules to cure diseases associated with elderly people. The research & development are further associated with small molecule therapeutics in canine oncology.
F. Hoffmann-La Roche Ltd to acquire acceptance from FDA for its Biologics License Applications. The application is associated with untreated diffuse large B-cell lymphoma.
Author Credits: Smruti Ranjan, Rajrani Baghel
Report ID: 4212
Published Date: May 01, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The growing presence of chronic diseases across the globe and the growing geriatric population are the major factors driving the growth of the market.
The market size of the Nervous System Active Pharmaceutical Ingredients Market is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2023-2035.
The major players in the market are Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Shenzhen Hepalink Pharmaceutical Co. Ltd., GSK plc, F. Hoffmann-La Roche Ltd, Cipla Inc., Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd.
The CVDs segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.